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Abstract
Background: The French EMS study prospectively collected exhaustive data from STS patients diagnosed in
the Rhone-Alpes region from 2005 to 07.
Methods: The database included diagnosis/histology, surgery, radiotherapy, systemic treatments and treatment
response. Treatment patterns and outcomes of patients with metastatic disease, excluding adipocytic sarcoma
and GIST were analyzed.
Results: Of 888 total patients, 145 were included based on having metastatic disease and appropriate
subtypes. All patients received treatment with systemic therapy being most common (74%, n = 107), followed
by radiotherapy (30%, n = 44) and surgery (23%, n = 33). Doxorubicin, alone or in combination, was the most
common first line systemic therapy (65%, n = 46). Drugs without license in sarcoma were used in 38–83% of
treatments depending on treatment line. 24% of frontline patients demonstrated an objective response,
decreasing to 11% objective responses in second line but no responses were documented beyond second
line, with median PFS declining with each additional line. Median PFS also declined in patients receiving
surgery compared to those receiving no surgery (8–15 m vs 5 m). Median OS from metastatic diagnosis for
patients receiving systemic therapy was double that of patients without systemic treatment (24 m vs 12 m,
p = 0.007).
Conclusions: Outcomes in this population were poor and declined with successive treatment. However,
results suggest that further anticancer therapies in recurrent sarcoma might be beneficial.
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Background
Soft tissue sarcomas (STS) are rare malignant tumours,
accounting for less than one percent of malignant neo-
plasms [1]. In France, the incidence of STS is estimated
at 6 per 100,000 per year with 4000 new cases diagnosed
each year [2]. With more than 50 distinct histological
subtypes described [3–5], management of STS is chal-
lenging due to its rarity and clinical heterogeneity. Con-
sequently, non-concordance in diagnosis occurs in 30%
of cases [6], potentially resulting in delayed or inappro-
priate treatment.
Half of all STS patients with intermediate or high-
grade tumors develop metastases [7]. Median survival is
approximately 12 to 18 months from the time of meta-
static diagnosis [8, 9], and has changed little in the past
two decades. Five-year survival is no more than 8% in
metastatic patients [8].
Chemotherapy is based on first-line anthracyclines,
most commonly doxorubicin [10], providing objective
responses in 12–26% of patients [11, 12]. The recent
development of targeted therapies such as the tyrosine
kinase inhibitor pazopanib [13] has led to hopes that the
therapeutic prospects of patients with metastatic STS
may be improved. Pazopanib demonstrated efficacy in a
randomised, double-blind, placebo-controlled Phase III
trial (PALETTE) in patients with metastatic STS (except
adipocytic sarcoma) who received prior chemotherapy
[14]. However, there are limited observational data on
real-world treatment of patients with metastatic STS
[15–17].
This study’s primary objective was to describe treat-
ment patterns of patients with metastatic STS for whom
pazopanib is labelled in a prospective registry of patients
with a primary diagnosis of sarcoma. Secondary objec-
tives were to determine survival rates and benefit of sys-
temic treatment on survival.
Methods
The EMS (Evaluation Médicale & Sarcome or Medical
Evaluation and Sarcoma) study was an observational,
prospective survey of patients with sarcoma from an
exhaustive patient cohort in the Rhône-Alpes region of
France over a 2-year period from March 2005 to March
2007. This sub-analysis considered all incident cases of
metastatic soft tissue sarcoma (STS) identified in the
database, corresponding to the subtypes eligible for the
PALETTE study. Data was collected from patient
records.
EMS patient database
The EMS study was initiated as a comprehensive pro-
spective population-based cohort in Rhône-Alpes in 2005,
including STS, GIST and osteosarcoma. The primary re-
ferral centres for inclusion in the database are the 43
pathology laboratories in this region, which accounts for
10% of the French population. All cases underwent central
histological review [18]. Methods for data collection in the
EMS database have been described previously [18, 19].
Patients
All patients with a diagnosis of primary sarcoma in-
cluded in the EMS database between 1st March 2005
and 28th February 2007 with metastatic disease (initially
or during follow up) were included in the present study.
The current analysis was restricted to patients with
histological subtypes included in the PALETTE trial of
pazopanib (i.e. key excluded subtypes: adipocytic sarcoma,
osteosarcoma, gastrointestinal stromal tumour) [14].
Data collection
Data in the EMS database included demographics, med-
ical history, diagnostic procedures, primary tumour char-
acteristics, functional status at diagnosis (ECOG score
[20]), treatments (surgery, radiotherapy or chemotherapy)
and outcomes according to the French 2006 SOR guide-
lines [20], follow-up recurrence and survival. It was noted
whether patients were treated in an expert centre [21, 22]
to describe the likely extent of collaboration between a
multi-disciplinary specialist STS medical team. Data was
prospectively extracted from the patient records covering
the period from first inclusion into the EMS database (be-
tween March 2005 and March 2007) until a cut-off point
of February 2012.
Statistical analysis
Data presentation is principally descriptive. Quantitative
data are presented as mean values ± standard deviation or
median values [range] and categorical data as frequency
counts and percentages. Overall survival, progression-free
survival and time to recurrence were analysed using time-
to-event analysis to generate Kaplan-Meier estimates with
95% confidence intervals. Missing data were not replaced.
Results
Patients
A total of 888 patients with a primary diagnosis of
sarcoma were available for analysis. Among these 888 pa-
tients, 358 (40%) adult patients (>18 years of age) corre-
sponded to the PALETTE trial’s eligibility criteria based
on tumour subtype (Additional file 1: Table S1). The mean
age at diagnosis was 61.5 ± 16.6 years and 47.2% of pa-
tients (169/358) were male. Of these 358 patients, 289
(80.7%) presented with a localised tumour and 69 (19.3%)
presented with metastatic disease at diagnosis. A further
76 (21.2%) patients with initially localised disease pro-
gressed to metastatic disease during the observation
period (2005–2012). The present analysis focuses on these
145 patients with metastatic disease.
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In the 145 patients with metastatic disease, 57% were
men with a mean age at diagnosis of 60 years for those
initially diagnosed with metastatic disease and 63 for
those diagnosed with local disease who went on to de-
velop metastases. The initial tumour site was visceral for
58% of patients, with a median time to progression of
12 m (95%CI 7-16 m) for those with initially local dis-
ease. Metastases were present in a single distant site in
93 patients (64.1%), in two distant sites in 37 patients
(25.5%) and in three or more distant sites in the
remaining 15 patients (10.3%). The principal metastatic
sites were the lung (103 patients; 71.0%), liver (35 pa-
tients; 24.1%), and bone (15 patients; 10.3%).
Treatment of metastatic sarcoma
All patients with metastases received at least one line of
treatment (surgery +/− radiotherapy +/− systemic treat-
ment), 83 patients (57.5%) received two treatment lines,
49 (33.8%) three lines and 29 (20.0%) four or more lines.
Treatments provided by line of therapy are presented in
Table 1. The first treatment line was principally systemic
treatment in more than two-thirds of patients (68.8%).
Surgery or radiotherapy for metastatic disease were used
in less than twenty percent of patients. Treatment across
modalities ((Metastatic Surgery (MS) +/− Radiotherapy
(RT) +/− Systemic treatment (ST)) was only received by
25 patients (22.5%) in 1st treatment line, 14 patients
(18.9%) in 2nd line and 1 patient (2.4%) in 3rd line. The
most frequent combinations were MS + ST (10%) and
RT + ST (14%).
Systemic treatments are described in Table 2. Among
the patients treated with a 1st line of systemic treatment,
one third (n = 36) received an experimental therapy in
the context of a clinical trial. In 2nd and 3rd line, around
27% of patients entered a clinical trial. Among the 71
patients receiving systemic treatment, 34 different che-
motherapeutic regimens were used.
For first line systemic treatment, the most frequently
used agent was doxorubicin in 46 patients (64.7%), either
in monotherapy (27 patients) or in combination (19 pa-
tients). In second line, the most frequently used agent
was gemcitabine, in 11 patients (25.6%), but there was
no drug that most clearly dominated second line treat-
ment or beyond. Drugs without a labelled indication for
STS were used with increasing frequency in later lines of
therapy.
Care management via sarcoma network
Care management in localized or metastatic disease was
usually initiated (91.0%) in centres outside the Netsarc/
GSF-GETO network (Table 3). In patients whose early
disease became metastatic, less than 7% of patients were
fully managed in the GSF-GETO network. For patients
with mSTS therapeutic decisions were partially/fully initi-
ated by the GSF-GETO network for 46.9% (68/145) of pa-
tients. The GSF-GETO network was more involved in
therapeutic decisions when metastatic STS was primarily
diagnosed (36 patients; 52.2%).
Clinical outcome
Clinical outcomes for patients with metastatic disease
are presented in Tables 4 and 5 and Additional file 2:
Table S2.
From the beginning of the first metastatic treatment, the
median time to relapse was 12.1 months (range: 1.1-72.2),
and this time decreased with each subsequent treatment
line. Similarly, response rates decreased with treatment line,
Table 1 Treatment of metastatic sarcoma by treatment line
Any treatment line 1st treatment line 2nd treatment line 3rd treatment line 4th or higher
treatment line
N = 145 N = 145 N = 83 N = 49 N = 52a
Metastatic Surgery (MS) 33 (22.8%) 25 (19.1%) 11 (14.5%) 1 (2.2%) 2 (3.9%)
Missing data 14 7 4 1
Radiotherapy (RT) 44 (30.3%) 20 (14.5%) 16 (20.5%) 6 (13.0%) 11 (22.0%)
Missing data 7 5 3 2
Systemic treatment (ST) 107 (73.8%) 95 (68.8%) 62 (78.5%) 35 (72.9%) 42 (82.4%)
Missing data 7 4 1 1
Treatment combinations N = 145 N = 111 N = 74 N = 41 -
MS + RT 2 (1.4%) 1 (0.9%) 1 (1.4%) 0 (0.0%) -
MS + ST 14 (9.7%) 11 (9.9%) 4 (5.4%) 0 (0.0%) -
RT + ST 20 (13.8%) 9 (8.1%) 8 (10.2%) 1 (2.4%) -
MS + RT + ST 5 (3.4%) 4 (3.6%) 1 (1.4%) 0 (0.0%) -
MD missing data are related to incomplete information regarding the specific types of treatment given
aas all treatment lines ≥ 4 were counted, the same individual patient may have been counted twice or more if they received multiple lines of treatment
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with no patients responding completely or partially after
the end of the second treatment line.
Progression free survival (PFS) was estimated (Fig. 1a)
according to 1st metastatic treatment. Although only
few patients received surgery for their metastatic disease,
it appears that patients selected for surgery exhibited im-
proved PFS but adjuvant treatment seems to do better
than surgery alone for PFS.
A similar approach was undertaken considering only
patients receiving systemic treatment (including n = 3
adjuvant/neoadjuvant systemic therapies). Similarly,
the time to relapse and response rates decreased with
each subsequent systemic treatment line (Tables 4
and 5, Fig. 1b). No patients responded completely or
partially after the end of the second systemic treat-
ment line.









N = 107 N = 59 N = 34d N = 18
Clinical triala
Yes 36 (33.6%) 16 (27.1%) 9 (27.3%) 0 (0.0%)
No 71 (66.4%) 43 (72.9%) 24 (72.7%) 18 (100.0%)
Treatment classa
Cytotoxic agent 65 (91.6%)b 37 (86.0%)b 22 (91.7%)b 12 (66.6%)b
Hormonal therapy 2 (2.8%) 1 (2.3%) 0 (0.0%) 0 (2.4%)
Targeted therapy 4 (5.6%) 5 (11.7%) 2 (8.3%) 6 (33.4%)
Treatment combinationsa
Monotherapy 38 (53.5%) 30 (69.8%) 9 (37.5%) 17 (94.4%)
Combination 33 (46.5%) 13 (30.2%) 15 (62.5%) 1 (0.6%)
Individual agenta,c
Doxorubicin 46 (64.7%) 10 (23.3%) 1 (4.2%) 0 (0.0%)
Ifosfamide 17 (23.9%) 6 (14.0%) 3 (12.5%) 1 (5.5%)
Dacarbazine 8 (11.3%) 1 (2.3%) 1 (4.2%) 0 (0.0%)
Gemcitabine 11 (15.5%) 11 (25.6%) 12 (50.0%) 2 (11.1%)
Docetaxel 11 (15.5%) 10 (23.3%) 10 (41.7%) 0 (0.0%)
Trabectedin 2 (2.8%) 9 (20.9%) 4 (16.4%) 7 (38.9%)
At least one off-label agent
Yes 27 (38.0%) 20 (46.5%) 20 (83.3%) 11 (61.1%)
No 44 (62.0%) 23 (53.5%) 4 (16.3%) 7 (38.9%)
apercentages are calculated with respect to the total number of patients receiving chemotherapy
bCertain patients (3 at 1st line, & at 2nd line, 2 at 3rd line and 2 at 4th or higher line) received a combination of a cytotoxic agent and a targeted therapy, the
classes of treatment used are therefore not mutually exclusive
cOnly the most frequently used agents are listed; these drugs are frequently used in combinations, so the drugs are not mutually exclusive
dTherapy data missing on 1 patient










N = 213 N = 76 N = 69 N = 358
Initial care by the NetSarc network N 213 76 69 358
No n (%) 196 (92.0%) 67 (88.2%) 62 (89.9%) 325 (90.8%)
Yes n (%) 17 (8.0%) 9 (11.8%) 7 (10.1%) 33 (9.2%)
Full treatment course N 213 76 69 358
Outside the GSF-GETO network n (%) 136 (63.8%) 44 (57.9%) 33 (47.8%) 213 (59.5%)
Care by the GSF-GETO network only n (%) 7 (3.3%) 5 (6.6%) 4 (5.8%) 16 (4.5%)
Mixed care n (%) 70 (32.9%) 27 (35.5%) 32 (46.4%) 129 (36.0%)
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The median overall survival from initial diagnosis with
sarcoma was 20.2 months (95% CI 15.9–27.0 m).
Comparing the overall survival of patients receiving
chemotherapy versus those who did not (Fig. 2), patients
receiving chemotherapy had significantly longer overall
survival (24.2 m [95% CI 17.4–33.6 m] vs. 11.8 m [95%
CI 6.5–19.6 m] p = 0.007). No sub-analysis was done by
performance status due to >50% missing data.
Discussion
The present study reported treatment patterns and out-
comes in patients with metastatic STS, excluding lipo-
sarcoma and GIST, enrolled in an exhaustive prospective
patient database in real life.
Of the entire STS population, 40.5% (145/358) were
diagnosed with or subsequently developed metastatic
disease. 26.3% (76/289) of patients with localised STS
had metastatic relapse, − half the rate of metastatic
relapse reported in the literature [23]. Previous hospital
case-series studies conducted in specialist centres may
be enriched with more severe patients at higher risk for
progression or relapse [17], whereas this study was
population based including all incident cases. In this
study, the treatment rate for metastatic STS in non-
specialist centres was lower, around 53%.
Systemic chemotherapy was the most common first-
line strategy for patients with metastatic STS with 68.8%
of patients receiving at least one line.
A large variety of systemic therapies were prescribed.
The European Society for Medical Oncology clinical prac-
tice guidelines for STS [24–26] have been updated regu-
larly since 2007 and in 2014. They confirm that although
there is no formal demonstration that multi-agent chemo-
therapy is superior to single agent doxorubicin therapy,
multi-agent chemotherapy with adequate-dose anthracy-
clines plus ifosfamide may be the treatment of choice for
Table 4 Treatment outcomes by treatment line
1st line 2nd line 3rd line 4th or higher line
N = 145 N = 83 N = 49 N = 52a
Time to relapse (months; median [range]) 12.1 [1.1–72.2]b 8.2 [1.2–37.9] 4.1 [0.5–27.7] 3.4 [0.7–23.2]
Treatment-free intervalc N = 46b N = 62 N = 35 N = 42
(months; median [range]) 10.2 [0.7–49.0] 2.9 [0.0–29.8] 1.0 [0.0–10.6] 1.0 [0.0–18.4]
Response at end of therapy N = 89 N = 61 N = 33 N = 36
Complete response (CR) 3 (3.4%) None None None
Partial response (PR) 19 (21.3%) 8 (13.1%) None None
Stable disease (SD) 19 (21.3%) 10 (16.4%) 4 (12.1%) 3 (8.3%)
Progressive disease 48 (54.0%) 43 (70.5%) 29 (87.9%) 33 (91.7%)
CP + PR 22 (24.7%) 8 (13.1%) None None
CP + PR + SD 41 (46.0%) 18 (29.5%) 4 (12.1%) 3 (8.3%)
aas all treatment lines ≥ 4 were counted, the same individual patient may have been counted multiple times with multiple treatment lines
bData only for patients without metastases at diagnosis
cTime between end of the previous systemic treatment and start of current treatment line (for 1st line: duration from initial diagnosis to first systemic therapy)









N = 107 (MD = 38) N = 59 N = 34 N = 18
Time to relapse (months; median [range]) 10.6 [1.1–72.2] 8.0 [1.4–27.4] 3.7 [0.5–27.7] 6.8 [1.6–21.5]
Treatment-free intervala N = 19 N = 58 N = 33 N = 18
(months; median [range]) 10.7 [0.7–49.0] 2.8 [0.0–19.6] 1.4 [0.0–18.4] 1.0 [0.0–5.8]
Response at end of therapy N = 102 N = 57 N = 32 N = 16
Complete response (CP) 3 (2.9%) None None None
Partial response (PR) 21 (20.6%) 6 (10.5%) None None
Stable disease (SD) 22 (21.6%) 7 (12.3%) 5 (15.6%) 2 (12.5%)
Progressive disease 56 (54.9%) 44 (77.2%) 27 (84.4%) 14 (87.5%)
CP + PR 24 (23.5%) 6 (10.5%) None None
CP + PR + SD 46 (45.1%) 13 (22.8%) 5 (15.6%) 2 (12.5%)
aTime between the end of the previous systemic treatment and the start of the current treatment line
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advanced disease, particularly when a tumour response is
felt to be potentially advantageous and patient perform-
ance status is good. During the EMS study enrolment
period, doxorubicin was recommended alone or in associ-
ation to other chemotherapies [25]. In this study, 64.7% of
patients receiving a systemic therapy were prescribed
doxorubicin, comparable to 70% previously documented
in the SABINE study [15]. In addition, 38% of patients in
the present study were prescribed unlicensed systemic
agents. Approved treatment options were limited, with
only anthracyclines, ifosfamide, dacarbazine and trabecte-
din being registered for use in sarcoma in France during
Fig. 1 a Kaplan Meier PFS curves for patients with metastatic disease according to 1st line treatment options. b Kaplan Meier PFS curves for
patients with metastatic disease according to systemic treatment lines
Fig. 2 Kaplan Meier OS curves for patients with metastatic disease according to whether chemotherapy was received
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this period. This may reflect physician perceptions of the
inadequacy of approved treatments. A similar perception
may underlie the relatively high proportion of patients
who are included in clinical trials. A high percentage of
patients (36%) were diagnosed with Sarcoma NOS, mak-
ing it difficult to understand whether a tailored treatment
might be impactful.
During subsequent treatment lines, no dominant treat-
ment protocol was observed with doxorubicin remaining
the most widely-used individual chemotherapeutic agent.
Although ifosfamide or dacarbazine are recommended
in ESMO guidelines for patients who fail to respond to
first-line doxorubicin, these agents were not widely used.
As in the SABINE study [15], the most widely used com-
bination was gemcitabine with docetaxel, in spite of the
fact that it is not registered for treatment of metastatic
STS. Trabectedin was used more frequently in second
and later treatment lines, consistent with the approved
indication and ESMO guidelines. Targeted therapies
were principally used in late treatment lines.
Clinical outcomes in this study population were poor
and declined with each successive line of treatment. Me-
dian time to relapse after first-line systemic treatment
was around one year, the treatment-free interval between
first- and second- line was around ten months.
Complete or partial response rates to first-line therapy
were less than 25%, which is similar to response rates
for anthracycline-based therapy published in the litera-
ture [11, 12] and no patients responded to third or
higher line treatments. Median overall survival was twice
as high in patients receiving chemotherapy versus those
who didn’t. This should be interpreted with caution, as
some patients might be too weak to be able to receive
chemotherapy, have comorbidities, or otherwise might
not be appropriate or wish to receive therapy, which
could impact the comparison. However, it is illuminating
to see a clear difference in OS between those receiving
and not receiving chemotherapy (24 m vs 12 m, p =
0.007), and is consistent with observations in breast and
ovarian cancer demonstrating chemotherapy being
linked with longer survival [27, 28]. Similar selection
bias combined with small patient numbers undergoing
surgery similarly limit the interpretation of the difference
in PFS according to surgery.
The heterogeneous approach to treatment and poor
outcome observed here and elsewhere emphasises the
need for better coordination of diagnosis and treatment.
In 2010, the French Cancer Institute (INCa) identified a
national network of regional Expert Centres for the
management of STS (NETSARC), composed mostly of
members of the French Sarcoma Group, called GSF-
GETO (Groupe Sarcome Français – Groupe d’Etude des
Tumeurs Osseuses). It is responsible for coordinating
care between the NETSARC expert STS medical team
and other oncologists in the territory in order to opti-
mise patient care. GSF-GETO published STS best prac-
tice guidelines in 2006 [20], conformity to which have
demonstrably improved PFS for sarcoma patients [29].
In this study, prior to NETSARC’s creation, the majority
of patients were managed outside GSF-GETO centres
both at initial diagnosis (91.0%) and during metastatic
disease (53.1%). There is no doubt that the NETSARC
network will improve the management of STS.
The study’s major strengths is the exhaustive coverage
using a patient registry, across a large French region, the
prospective design allowing complete documentation of
the disease, and the naturalistic setting in routine clinical
practice in France. This analysis was limited to patients
with STS with relapsing disease with subtypes included
in the PALETTE study.
Conclusion
In conclusion, this study demonstrates that treatment of
metastatic STS in everyday practice in Rhone-Alpes re-
gion is highly heterogeneous and associated with poor
outcomes. This highlights the significant unmet medical
needs with respect to standardised treatment protocols
and more effective therapies.
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